Physician profile
Steven Pedro
NPI 1982634481
$4,608.84
in general payments reported to CMS, 2019-2025
22 companies · $978 in 2025
The $978 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $186 · 2021: $233 · 2022: $767 · 2023: $1,470 · 2024: $393 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $652.65 | 2019-2024 | Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $528.48 | 2023-2025 | Zoryve |
| Abbvie INC. | $433.96 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $390.83 | 2021-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $382.48 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $294.51 | 2023-2024 | Vtama |
| Genzyme Corporation | $247.51 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $194.00 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.66 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $169.98 | 2020-2023 | Arazlo |
| Janssen Scientific Affairs, LLC | $146.31 | 2025 | Tremfya |
| Pfizer INC. | $138.86 | 2020-2024 | |
| Galderma Laboratories, L.P. | $134.44 | 2019 | |
| Amgen INC. | $134.07 | 2022 | |
| Incyte Corporation | $130.37 | 2022-2023 | Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $106.06 | 2023 | Ilumya |
| Janssen Biotech, INC. | $99.28 | 2019-2023 | Simponi Aria, Simponi, Remicade |
| Organon LLC | $74.40 | 2025 | Vtama |
| Merz North America, INC. | $73.02 | 2019 | |
| Mayne Pharma Commercial LLC | $45.25 | 2022 | |
| Allergan, INC. | $26.58 | 2022 | |
| Bausch Health US, LLC | $17.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pedro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.